Skip to main navigation Skip to search Skip to main content

Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-Resistant Schistosoma Species

  • Sevan N. Alwan
  • , Alexander B. Taylor
  • , Stanton F. McHardy
  • , Michael D. Cameron
  • , Philip T. LoVerde
  • University of Texas Health Science Center at San Antonio
  • University of Texas at San Antonio
  • University of Florida

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Schistosomiasis, a neglected tropical disease affecting over 250 million people worldwide, relies on praziquantel (PZQ) as its sole treatment. However, PZQ has significant limitations, including inactivity against juvenile worms, inability to prevent reinfection, and emerging drug resistance. In this review, we outline the development of CIDD-0150303, a novel oxamniquine (OXA) derivative with pan-species and pan-stage activity against Schistosoma mansoni, PZQ-resistant S. mansoni, and S. haematobium. Using a structure-guided design approach, over 350 OXA analogs were synthesized and screened to identify leading drug candidate CIDD-0150303. CIDD-0150303 demonstrates 100% lethality in vitro and up to 80% reduction in worm burden in vivo. CIDD-0150303 is effective against both juvenile and adult parasites as well as PZQ-resistant S. mansoni. This compound represents a promising advance in schistosomiasis treatment to address urgent gaps in control/elimination strategies and PZQ resistance. However, dedicated safety and toxicity studies are still ongoing, and additional in vivo validation is required.

Original languageEnglish
Article number1268
JournalPharmaceutics
Volume17
Issue number10
DOIs
StatePublished - Oct 2025

Keywords

  • Schistosoma
  • drug discovery
  • drug resistance
  • oxamniquine

Fingerprint

Dive into the research topics of 'Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-Resistant Schistosoma Species'. Together they form a unique fingerprint.

Cite this